GTBP
GT Biopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$16.91M
P/E Ratio
—
EPS
$-6.46
Beta
0.64
52W High
$3.85
52W Low
$0.26
50-Day MA
$0.39
200-Day MA
$0.67
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
17.33
PEG Ratio
1.05
About GT Biopharma Inc
GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-6.76M |
| Operating Margin | 0.00% |
| Return on Equity | -922.00% |
| Return on Assets | -131.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.21 |
| Price-to-Book | 2.00 |
| Price-to-Sales (TTM) | 204.96 |
| EV/Revenue | 773.27 |
| EV/EBITDA | -0.09 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $35.62M |
| Float | $33.17M |
| % Insiders | 3.42% |
| % Institutions | 6.87% |
Historical Volatility
HV 10-Day
219.72%
HV 20-Day
173.79%
HV 30-Day
150.29%
HV 60-Day
116.95%
HV Rank
84.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($3.00 target)
1
BuyMore HEALTHCARE Stocks
Data last updated: 5/23/2026